Compare PLXS & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLXS | ARQT |
|---|---|---|
| Founded | 1979 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 1986 | 2020 |
| Metric | PLXS | ARQT |
|---|---|---|
| Price | $153.07 | $28.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $160.00 | $24.83 |
| AVG Volume (30 Days) | 220.3K | ★ 2.0M |
| Earning Date | 01-21-2026 | 10-28-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 56.11 | N/A |
| EPS | ★ 6.26 | N/A |
| Revenue | ★ $4,032,966,000.00 | $317,929,000.00 |
| Revenue This Year | $10.99 | $85.51 |
| Revenue Next Year | $7.02 | $30.74 |
| P/E Ratio | $24.49 | ★ N/A |
| Revenue Growth | 1.82 | ★ 129.21 |
| 52 Week Low | $103.43 | $11.13 |
| 52 Week High | $172.89 | $31.77 |
| Indicator | PLXS | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 53.86 | 51.12 |
| Support Level | $147.43 | $27.55 |
| Resistance Level | $166.91 | $28.90 |
| Average True Range (ATR) | 6.10 | 1.15 |
| MACD | -0.31 | -0.55 |
| Stochastic Oscillator | 42.46 | 18.58 |
Plexus Corp designs, manufactures, and services complex products in demanding regulatory environments, supporting life-saving medical devices, mission-critical aerospace and defense products, industrial automation systems, and semiconductor capital equipment. Its integrated lifecycle solutions span design and development, supply chain solutions, new product introduction, manufacturing, and sustaining services for market and disruptive companies in the Aerospace/Defense, Healthcare/Life Sciences, and Industrial sectors. The Company operates through three reportable segments: AMER, APAC, and EMEA, with the majority of revenue from the APAC segment.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.